Skip to main content


We're creating a new version of this page. See preview

  • ePoster presentation
  • Open Access

Production of cross neutralizing single chain fragment variables (scFv) from HIV-1 infected Indian children

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 3 and
  • 1Email author
BMC Infectious Diseases201414 (Suppl 3) :E25

  • Published:


  • Infected Child
  • Phage Library
  • Single Chain Fragment Variable
  • Fingerprinting Analysis
  • Phage ELISA


Monoclonal antibody based vaccines are effective and highly specific in disease targeting. Presently, most of the existing broadly neutralizing antibodies are generated against non subtype c viruses. HIV-1 subtype c accounts for more than 90% of infection in India. The disease progression in children is faster than adults.


Nine ART drug naïve HIV-1 subtype c infected children were recruited. PBMCs were isolated from all the subjects and pooled. RNA was isolated and cDNA was synthesized followed by amplification of VH and VL chain genes and scFv construction. A human recombinant scFv phage display library of 108 clones was constructed. Diversity of the phage library was checked by DNA sequencing and biopanned with RSC3 core antigen. 60 random clones were screened by phage ELISA. Expression of the scFvs was assessed by SDS-PAGE and Western blotting.


The diversity of the phage library was more than 90%. Eight scFv monoclonals showed positive binding in phage ELISA and two best binders were further characterized. Both scFvs didn’t show any reactivity with unrelated antigens. DNA fingerprinting analysis showed both scFvs were distinct. A 32kDa band was obtained in SDS-PAGE and Western blot. Both scFvs showed cross neutralizing activity against a standard panel of pseudoviruses.


Here, we have for the first time generated a human recombinant scFv phage display library containing neutralizing clones from HIV-1 infected children. Further characterization of these scFvs generated against CD4 binding site for their epitope mapping would be helpful in the development of an effective HIV-1 vaccine.

Authors’ Affiliations

Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India
Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India
National Brain Research Centre (NBRC), Gurgaon, Haryana, India


© Kumar et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.